Pharmaceutical firm Eli Lilly has reported a doubling in global sales for its diabetes and weight loss injection Mounjaro, fuelled by surging market appetite.
The drugmaker highlighted that its obesity treatments, Mounjaro and Zepbound, are spearheading a broader surge in company revenues.